Table 1 Characteristics of published articles and errata on COVID-19 therapeutics research articles
N (%) | ||
|---|---|---|
Articles, N = 18 | Study type | |
Clinical trial | 15 (83.3) | |
Systematic review | 2 (11.1) | |
Observational study | 1 (5.5) | |
Year of publication | ||
2020 | 6 (33.3) | |
2021 | 10 (55.5) | |
2022 | 2 (11.1) | |
Journal impact factor | ||
0–2 | 4 (22.2) | |
3–9 | 6 (33.3) | |
> 10 | 8 (44.4) | |
Geographic region—first author | ||
Asia | 9 (50) | |
Europe | 4 (22.2) | |
North America | 2 (11.1) | |
South America | 3 (16.6) | |
Erratum, N = 19 | Time to erratum publication (days) | |
0–60 | 7 (36.8) | |
61–120 | 6 (31.5) | |
121–240 | 5 (26.3) | |
> 240 | 1 (5.3) | |
Online publication corrected | ||
Yes | 9 (47.3) | |
No | 10 (52.6) |